SPOTLIGHT: Meridian buys recombinant proteins

Meridian Bioscience has agreed to buy a line of infectious disease recombinant proteins from Vybion for an undisclosed sum of money. The pact covers future royalties on product sales. Release | Report

Suggested Articles

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.

In our EuroBiotech roundup this week, a liver disease biotech raises €11 million, Autolus offers stock and Abivax plans midphase trial.